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Abstract: Lenalidomide (also known as Revlimid®, CC-5013) is an immunomodulatory 
derivative of thalidomide and has more potent anti-tumor and anti-inﬂ  ammatory effects than 
thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been 
extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. 
Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; 
inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal 
cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments 
host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory 
MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM 
activities than Dex both in vitro and in randomized phase III clinical trials. Speciﬁ  cally, the 
combination improved overall and extent of response, as well as prolonged time to progression 
and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM 
relapsing after prior therapy.
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Introduction
Multiple myeloma (MM) is a B cell malignancy characterized by excess monotypic 
plasma cells in the BM in association with monoclonal protein in serum and/or urine, 
decreased normal immunoglobulin (Ig) levels, and lytic bone disease. The 2006 
estimate of multiple myeloma incidence in the United States is 16,570 cases, with an 
estimated number of 11,300 deaths. Conventional therapies with alkylating agents, 
anthracyclines, and corticosteroids can extend patient survival to a median of 3–4 
years (Gregory et al 1992; Group 1998), and high dose therapy followed by autolo-
gous transplantation can modestly prolong median survival to 4–5 years (Fermand 
et al 1998; Lenhoff et al 2000). Attempts to improve autografting include repeated 
use of high dose therapies (Desikan et al 2000; Attal et al 2003), as well as immune 
strategies to treat minimal residual disease post-transplant (Massaia et al 1999) can 
improve outcome in some studies, few, if any, patients are cured. MM remains incur-
able due to the development of tumor cell resistance to all therapies, highlighting the 
urgent need for novel treatment strategies.
Thalidomide (Thal) has shown to be useful in various diseases including MM; 
however, it is a potent teratogen and causes side effects including peripheral neuropathy 
(Tseng et al 1996). Attempts were therefore made to develop Thal analogs which are 
more potent and have less adverse effects: lenalidomide (C13H13N3O3, MW = 259.26) is 
one such analog belonging to the class oﬁ  mmunomodulatory drugs (IMiDs) developed 
by the drug discovery program.Therapeutics and Clinical Risk Management 2008:4(1) 130
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Preclinical studies of lenalidomide
Overview (Figure 1)
The interaction of multiple myeloma (MM) cells with bone 
marrow (BM) extracellular matrix (ECM) proteins and BM 
accessory cells, BM stromal cells (BMSCs), osteoblasts, 
osteoclasts, endothelial cells, as well as other factors in 
the BM milieu (ie, cytokines, angiogenesis) plays a crucial 
role in MM pathogenesis and drug resistance (Damiano 
et al 1999; Akiyama et al 2002; Hideshima and Anderson 
2002; Hideshima et al 2003, 2004, 2006; Chauhan et al 
2004). These accessory cells not only physically interact 
with MM cells, but also secrete growth and/or anti-
apoptotic factors such as interleukin (IL)-6, insulin-like 
growth factor (IGF)-1, vascular endothelial growth factor 
(VEGF), and tumor necrosis factor (TNF)-α (Akiyama 
et al 2002; Chauhan et al 1996, 2004, 2005; Catley et al 
2004; Hideshima et al 2006). Delineation of the mecha-
nisms of BM stromal cell (SC)-mediated MM cell prolif-
eration, survival, drug resistance, and migration therefore 
provides the framework for identiﬁ  cation and validation 
of novel therapeutic targets.
Within the BM microenvironment, several proliferative/
antiapoptotic signaling cascades are activated in MM cells: 
phosphatidylinositol-3 kinase (PI3K)/Akt (also known as 
protein kinase B); I κ B kinase (IKK)/nuclear factor κ-B 
(NFκB); Ras/Raf/mitogen-activated protein kinase (MAPK) 
kinase (MEK)/extracellular signal-related kinase (ERK); and 
Janus kinase (JAK) 2/signal transducers and activators of 
transcription (STAT)-3 (Figure 1, Table 1). These signaling 
cascades mediate: cytoplasmic sequestration of many tran-
scription factors; upregulation of cyclin D and anti-apoptotic 
Bcl-2 family members; as well as augmentation of telom-
erase activity (Hideshima et al 2001a; Akiyama et al 2002). 
Importantly, these molecular events are triggered by both 
MM cell adherence to BMSCs and by cytokines secreted 
from BMSCs (Dankbar et al 2000; Hideshima et al 2004; 
Mitsiades et al 2004). Cytokines secreted from MM cells 
and BMSCs and other cells may in turn further augment 
cytokine secretion.
Novel biologically based agents target not only the 
MM cell, but also MM cell–host interactions, cytokines, 
and their sequelae in the BM milieu. Thalidomide and 
Figure 1 Potential mechanisms of action of anti-MM activity of lenalidomide. Lenalidomide: directly induces tumor cell apoptosis and/or growth arrest (A); enhances NK 
and/or NK cell activity via activation of CD28/NF-AT2 pathway (B); inhibits MM cell adhesion to host microenvironment (C); inhibits angiogenesis (D); inhibits osteoclasto-
genesis (E); as well as inhibits cytokine secretion (F).Therapeutics and Clinical Risk Management 2008:4(1) 131
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its immunomodulatory derivative (IMiD) lenalidomide 
(Revlimid®; Celgene Corp., Summit, NJ, USA) are examples 
of such agents targeting the tumor cell in its BM milieu 
which can achieve responses even in refractory relapsed MM. 
Lenalidomide may inhibit MM cell growth by several differ-
ent mechanisms (Figure 1). First, lenalidomide has a direct 
effect on MM cells to induce G1 growth arrest or apoptosis 
even of drug resistant cells (Hideshima et al 2000; Mitsiades 
et al 2002). Second, lenalidomide inhibits adhesion of MM 
cells to BMSCs, and thereby can overcome cell adhesion 
mediated drug resistance (CAM-DR); third, lenalidomide 
inhibits bioactivity and/or secretion in MM cells and/or BM 
stromal cells of cytokines [eg, interleukin (IL)-6, IL-1β, 
IL-10, and tumor necrosis factor (TNF)α] which augment 
MM cell growth, survival, drug resistance, migration, and 
expression of adhesion molecules. Importantly, lenalidomide 
is several thousand fold more potent than Thal at inhibiting 
TNFα/IL-1β secretion from mononuclear cells stimulated 
with lipopolysaccharide (LPS) in vitro (Corral et al 1999; 
Muller et al 1999). Fourth, vascular endothelial growth fac-
tor (VEGF) and basic ﬁ  broblast growth factor (bFGF) are 
secreted by MM cells and/or BMSCs, and lenalidomide may 
inhibit activity of VEGF, bFGF, and angiogenesis in MM. 
Lenalidomide also acts against MM through immunomodu-
latory effects such as augmentation of activity of cytotoxic 
T-cells and natural killer (NK) cells, associated with secretion 
of IL-2 and interferon-γ (Davies et al 2001; LeBlanc et al 
2004; Hayashi et al 2005).
Bone destruction is a hallmark of MM, with 70%–80% of 
patients manifesting bone involvement. Recently, Anderson 
et al demonstrated that an IMiD CC-4047 (Actimid®; Celgene 
Corp., Summit, NJ, USA) inhibits osteoclastgenesis via 
downregulation of transcription factor PU.1 (Anderson et al 
2006). Lenalidomide also has inhibitory effect on osteoclas-
togenesis (Terpos et al 2007).
Direct anti-tumor activities
of lenalidomide
Although the targets of whereby lelalidomide mediates anti-
tumor activity of lenalidomide have not been fully delineated, 
several studies have examined the molecular mechanisms 
mediating sequelae of lenalidomide. Our previous studies 
demonstrated that lenalidomide induces G0/G1 growth arrest 
associated with p21Cip1 upregulation and/or apoptosis which 
is mediated via caspase-8 activation (Hideshima et al 2000; 
Mitsiades et al 2002). Lenalidomide inhibits LPS-mediated 
induction of Cox-2 and prostaglandin E2 (PGE2) production by 
a post-transcriptional mechanism in RAW 364.7 cells (Fujita 
et al 2001), suggesting that the anti-tumor activity induced 
by lenalidomide may also be due to inhibition of Cox-2 and 
PGE2. Lenalidomide inhibits nuclear factor (NF)-κB subunit 
activity in MM cell lines (Mitsiades et al 2002), which is 
consistent with reports that Thal inhibits DNA binding activ-
ity of the p50/p65 NF-κB triggered by TNFα and IL-1β in 
Jurkat cell line (Keifer et al 2001) and in PBMCs (Rowland 
et al 2001). Since NF-κB plays an essential role in cell cycle 
regulation, cell survival, anti-apoptosis, and cytokine produc-
tion in MM cells (Hideshima et al 2001b, 2002), inhibition of 
NF-κB activity by lenalidomide may also enhance or restore 
sensitivity to other chemotherapeutic agents. Speciﬁ  cally, we 
have demonstrated that MM cell adhesion-mediated upregula-
tion of IL-6 is mediated via NF-κB activation (Chauhan et al 
1996; Hideshima et al 2002). Recently, Stewart et al (2004) 
reported pharmacogenomic studies suggesting that hyperac-
tivation of the Wnt signaling antagonist DKK-1 is associated 
with response to the immunomodulators Thal and lenalido-
mide. Furthermore, β-catenin expression is downregulated 
by lenalidomide in MM cell lines.
Lenalidomide in combination with Dex is one of the most 
promissing MM novel treatment options. It induces at least 
additive direct cytotoxicity in MM cells (Hideshima et al 
2000), associated with activation of dual apoptotic signal-
ing cascades: Dex induces caspase-9 (Chauhan et al 2001; 
Hideshima et al 2001a) and lenalidomide triggers caspase-8 
activation (Mitsiades et al 2002) (Figure 2). Most recently, 
enhanced anti-MM activity of rapamycin, a speciﬁ  c mTOR 
inhibitor, in combination with lenalidomide has been reported 
(Raje et al 2004). In this study, the combination of rapamycin 
plus lenalidomide overcomes drug resistance in MM cell 
lines resistant to conventional chemotherapy. Interestingly, 
differential signaling cascades, including the ERK and PI3-
K/Akt pathways, are targeted by these drugs individually 
and in combination, suggesting the molecular mechanism 
by which they inhibits MM growth and survival.
Table 1 Selected ongoing clinical trials of lenalidomide based 
combination treatment in multiple myeloma
Agent Phase  Patient
Perifoine + Dex  I  Rel/ref
Hepatitis B vaccine  I  Rel/ref
Doxorubicin + Dex I/II  Rel/ref
Bortezomib + Dex I/II  Newly  diagnosed
Bortezomib + Dex II  Rel/ref
Bevacizumab + Dex II  Rel/ref
Clarithromycin + Dex II  Newly  diagnosed
Dex III  Newly  diagnosed
Dex III  Previously  treated
Dex IV  Previously  treatedTherapeutics and Clinical Risk Management 2008:4(1) 132
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Anti-angiogenic activity
Previous studies have shown that oral administration of 
lenalidomide attenuates growth factor-induced angiogenesis 
in vivo. This effect is correlated with the inhibitory effect 
of lenalidomide on growth factor-induced Akt phosphoryla-
tion, thereby providing a potential mechanism for its anti-
migratory and subsequent anti-angiogenic effects (Dredge 
et al 2005). In MM, an anti-angiogenic effect of Thal in 
vitro has been demonstrated (D’Amato et al 1004; Singhal 
et al 1999; Lentzsch et al 2002; Fujita et al 2004); however, 
to date no strong evidence of an anti-angiogenic effect of 
lenalidomide in vivo has been demonstrated. Moreover, 
Singhal et al (1999) reported no correlation of BM angiogen-
esis with response to Thal in patients with relapsed refractory 
MM, suggesting that lenalidomide may mediate its anti-MM 
activity via mechanisms other than anti-angiogenesis.
Immunomodulatory activities
A unique feature of the anti-tumor effect of Thal and lenalido-
mide is their ability to modulate and potentiate host immune 
responses against MM. Several studies have demonstrated 
the effects of lenalidomide on peripheral blood lymphocytes 
(Davies et al 2001; Haslett et al 2003; LeBlanc et al 2004; 
Hayashi et al 2005). Co-culture of naive splenocytes with 
anti-CD3 monoclonal antibody and IMiD1 (Actimid®) 
directly costimulates T cells and increases Th-1-type cyto-
kines. Most excitingly, IMiDs augment CTL and NK cell 
activity against MM cell lines and autologous MM cells, 
associated with increased IL-2 levels in serum (Davies et al 
2001). Although Thal/IMiDs induce IL-2 secretion from 
T cells (Corral et al 1999; Shannon et al 2000), the mecha-
nisms whereby these compounds induce IL-2 production 
from T cells has not totally been deﬁ  ned. Importantly, our 
recent studies demonstrated that lenalidomide signiﬁ  cantly 
costimulates proliferation of CD3+ T cells induced by CD3 
ligation, immature dendritic cells (DCs; SI, 2.1), or mature 
DCs (SI, 2.6). T-cell proliferation triggered by DCs is abro-
gated by cytotoxic T lymphocyte antigen 4-immunoglobulin 
(CTLA-4-Ig). Lenalidomide also overcomes the inhibitory 
effects of CTLA-4-Ig on Epstein-Barr virus and inﬂ  uenza-
speciﬁ  c CD4 and CD8 T-cell responses, as measured by 
cytokine capture and enzyme-linked immunosorbent spot 
(ELISPOT) assays. Importantly, lenalidomide triggers 
tyrosine phosphorylation of CD28 on T cells, followed by 
activation of NF-κB (LeBlanc et al 2004). Furthermore, we 
have demonstrated that IMiDs facilitate the nuclear translo-
cation of nuclear factor of activated T cells (NF-AT)-2 and 
activator protein-1 via activation of PI3-K/Akt signaling, 
with resultant IL-2 secretion. IMiDs enhance both NK cell 
cytotoxicity and ADCC induced by triggering IL-2 produc-
tion from T cells (Hayashi et al 2005). These studies therefore 
deﬁ  ne the molecular mechanisms whereby lenalidomide trig-
gers NK cell-mediated cytotoxicity against MM cells, further 
supporting their therapeutic use in MM. More recently, we 
have shown that lenalidomide enhances ADCC induced by 
SGN-40, a humanized IgG1 anti-CD40 monoclonal antibody 
(Tai et al 2005).
Clinical studies of lenalidomide
Pharmacokinetics
Pharmacokinetics (PK) of lenalidomide in MM patients 
has been reported by Wu and Schefﬂ  er (2004) at American 
Society of Clinical Oncology in 2004. In this single-center, 
open-label, non-randomized, phase I dose escalation study 
in relapsed and refractory MM, the doses of lenalidomide 
used were 5, 10, 25 or 50 mg/day orally for 28 days. Blood 
samples were collected before and at 15 min, 30 min, 45 min, 
1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 18 h, 24 h, 
48 h, and 72 h after administration on both days 1 and 28. No 
lenalidomide dose-limiting toxicity was observed at any dose 
level within the ﬁ  rst 28 days. Absorption of lenalidomide was 
rapid on both day 1 and 28, with tmax ranging from 0.7 to 2.0 h 
Figure 2 Potential mechanisms of synergistic cytotoxicity by lenalidomide plus 
Dex treatment in MM cells. Lenalidomide triggers caspase-8 dependent apoptosis, 
whereas Dex induces caspase-9 dependent apoptosis. The combination therefore 
triggers dual apoptotic signaling cascades.Therapeutics and Clinical Risk Management 2008:4(1) 133
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at all dose levels. Plasma levels of lenalidomide declined in a 
monophasic manner, with elimination half-life ranging from 
2.8 to 6.1 h on both days 1 and 28 at all four doses. No plasma 
accumulation was observed upon multiple dosing. Importantly, 
daily oral doses of lenalidomide up to 50 mg produced no 
dose-limiting toxicity within the ﬁ  rst 28 days.
The other PK study has been reported by Richardson et al 
(2006). In this study, plasma concentration of lenalidomide 
was determined in 39 patients during the ﬁ  rst and second 
cycles in both 15 mg and 30 mg dose groups, and when Dex 
was added due to progressive disease (PD) or stable disease 
(SD) on lenalidomide alone. The mean minimum (Cmin) 
plasma lenalidomide concentrations on days 1, 2, 3, 4, and 
21 during the ﬁ  rst and second 21-day cycles of lenalidomide 
alone and with the addition of Dex are shown for the 30 mg 
once-daily and 15 mg twice-daily cohorts. The average Cmin 
plasma levels were less in the twice-daily compared with 
daily dosing regimens. No obvious effect on lenalidomide 
plasma concentrations was seen with addition of Dex in either 
once- or twice-daily treatment.
Clinical trials of lenalidomide
Only a limited number of reports are available for clini-
cal studies of lenalidomide (Bartlett et al 2004). A phase I 
clinical study of lenalidomide was completed at Dana-Farber 
Cancer Institute (Richardson et al 2002a). In this study, 
dose-escalation (5 mg/day, 10 mg/day, 25 mg/day, and 
50 mg/day) of lenalidomide was evaluated in 27 patients 
(median age 57 years; range, 40–71 years) with relapsed 
and refractory relapsed MM (Richardson et al 2002b). These 
patients received a median of 3 (range, 2–6) prior regimens, 
including autologous stem cell transplantation and Thal in 
15 and 16 patients, respectively. In 24 evaluable patients, 
no dose-limiting toxicity (DLT) was observed in patients 
treated at any dose level within the ﬁ  rst 28 days; however, 
grade 3 myelosuppression developed after day 28 in all 13 
patients treated with 50 mg/day lenalidomide. Dose reduction 
to 25 mg/day was well tolerated in 12 patients and therefore 
considered to be the maximal tolerated dose (MTD). Most 
importantly, no signiﬁ  cant somnolence, constipation, or 
neuropathy, the most common toxicities of Thal, have been 
seen in any cohort. Best responses of at least 25% reduction 
in paraprotein occurred in 17 of 24 (71%) patients (90% 
conﬁ  dence interval [CI], 52%–85%), including 11 (46%) 
patients who had received prior Thal; stable disease (less 
than 25% reduction in paraprotein) was observed in an addi-
tional 2 (8%) patients. This study therefore demonstrates that 
lenalidomide can overcome conventional drug resistance, 
even resistance to Thal. Given that lenalidomide is an oral 
agent, it is currently being evaluated in a randomized trial 
post autografting in an attempt to prolong progression free 
and overall survival.
A multicenter, open-label, randomized phase II study 
to evaluate 2 dose regimens of lenalidomide for relapsed, 
refractory MM has been performed. In this study, 70 patients 
were randomized to receive either 30 mg once-daily or 15 mg 
twice-daily oral lenalidomide for 21 days of every 28-day 
cycle. An additional 32 patients received 30 mg once daily. 
Patients with progressive or stable disease after 2 cycles 
received additional Dex. Responses were evaluated according 
to European Group for Blood and Marrow Transplantation 
(EBMT) criteria. Overall response rate (CR+PR+MR) to 
lenalidomide alone was 25%; 24% for 30 mg once-daily and 
29% for 15 mg twice-daily cohort. Median overall survival in 
30-mg once-daily and 15 mg twice-daily groups was 28 and 27 
months, respectively. However, median progression-free sur-
vival was 7.7 months on 30 mg once-daily versus 3.9 months 
on 15 mg twice-daily lenalidomide. Dex was added in 68 
patients and 29% responded. Importantly, time to ﬁ  rst occur-
rence of clinically signiﬁ  cant grade 3/4 myelosuppression 
was shorter in the 15 mg twice-daily group (1.8 months) than 
30 mg once-daily (5.5 months, p = 0.05) group. Moreover, 
analysis of the ﬁ  rst 70 patients showed increased grade 3/4 
myelosuppression in patients receiving 15 mg twice-daily 
(41% vs 13%, p = 0.03). This study indicate that lenalidomide 
is active and well tolerated in relapsed, refractory myeloma, 
with the 30-mg once-daily regimen providing the basis for 
future studies as monotherapy and with Dex (Richardson 
et al 2006).
Clinical studies of lenalidomide
in combination with Dex
As described above, preclinical studies have demonstrated 
the efﬁ  cacy of combination treatment of lenalidomide with 
Dex in MM and several clinical trials of this combination 
treatment have been completed.
In two double blind, multicenter, international phase 
III clinical trials (MM-009, North American, 353 patients; 
MM-010, Europe, Australia, and Israel, 351 patients), 
patients with relapsed or refractory MM not resistant to Dex 
were treated with Dex 40 mg daily on days 1–4, 9–12, and 
17–20 every 28 days and were randomized to receive either 
lenalidomide 25 mg daily orally on days 1–21 every 28 days 
or placebo. At a median follow-up from randomization of 
17.1 months (MM-009) and 16.5 months (MM-010), both 
studies show signiﬁ  cant improvement with lenalidomide Therapeutics and Clinical Risk Management 2008:4(1) 134
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plus Dex compared to Dex in overall response (OR) 
(MM-009: 1% vs 20.5%, p   0.001; MM-010: 59.1% 
vs 24%, p   0.001, respectively), time to progression 
(TTP) (MM-009: 11.1 months vs 4.7 months, p   0.001; 
MM-010: 11.3 months vs 4.7 months, p   0.001, respec-
tively), and overall survival (OS) (MM-009: 29.6 months 
vs 20.5 months, p   0.001; MM-010: not estimable vs 20.6 
months, p   0.001, respectively). In a subgroup analysis on 
patients with impaired creatinine clearance, no signiﬁ  cant 
difference in response rate, TTP, or OS was observed in 
patients with creatinine clearance above or below 50 mL/
min who were treated with lenalidomide plus Dex; however, 
for 16 patients with creatinine clearance  30 mL/min, 
median TTP and OS was shorter than for those with creati-
nine clearance  30 mL/min, but still signiﬁ  cantly longer 
than for patients treated with Dex (Weber et al 2006).
Treatment with lenalidomide plus Dex in newly diagnosed 
MM patients has also reported by Rajkumar et al (2005). In 
this study, lenalidomide was given orally 25 mg daily on days 
1–21 of a 28-day cycle. Dex was given orally 40 mg daily 
on days 1–4, 9–12, and 17–20 of each cycle. Thirty-one of 
34 patients achieved an objective response, including 2 (6%) 
achieving complete response (CR) and 11 (32%) meeting 
criteria for both very good partial response and near complete 
response, resulting in an overall objective response rate of 
91%. This study indicated that lenalidomide plus Dex is a 
highly active regimen with manageable side effects in the 
treatment of newly diagnosed MM.
A number of studies demonstrated that MM is character-
ized by cytogenetic abnormalities causing dysregulation of 
the genes at the breakpoints, and by point mutations (Kuehl 
et al 2002; Fonseca et al 2004; Carrasco et al 2006). Spe-
ciﬁ  cally, chromosome 13 deletions are present in over 50% 
of MM patients and considered to be associated with poor 
prognosis. In addition, t(4; 14) in MM also predicts poor 
response to conventional and high dose treatment and short-
ened survival. A recent study has shown that lenalidomide 
overcomes the poor prognosis conferred by chromosome 13 
deletion and t(4; 14) in MM patients, evidenced by event free 
survival and response rate (Bahlis et al 2006).
Recently, a phase I/II 3 combination treatment of 
lenalidomide, Dex and adriamycin (RAD therapy) for 
relapsed MM patient has been reported. In this study, 31 
patients were evaluated for response and toxicity: 26 patients 
achieved reduction of paraprotein levels of at least 50% for 
a response rate of 84%, including one conﬁ  rmed CR and 
14 PRs according to the EBMT criteria. Importantly, 8 of 
10 patients who displayed del (13) on cytogenetic analysis 
responded, including 6 conﬁ  rmed PRs. One patient each 
experienced acute renal failure due to emesis and hypo-
volemia, pneumocystis pneumonitis, and catheter related 
infection. Somnolence, constipation, thromboembolism, 
or neuropathy was not observed. This study showed that 
RAD induces substantial responses with an acceptable 
toxicity proﬁ  le, and thus signiﬁ  cantly contributes to the 
therapeutic armamentarium even in heavily pretreated MM 
patients (Knop et al 2006). Most recently, a phase I study of 
lenalidomide and dexamethasone in combination with Akt 
inhibitor perifosine for patients with relapsed or refractory 
MM, and a phase I/II study of lenalidomide, dexamethasone 
and bortezomib combination therapy for newly diagnosed 
MM patients are ongoing.
The common side effects of lenalidomide treatment in 
phase 2 clinical trials of relapsed refractory MM are sum-
marized in Table 1. The most common toxicities associated 
with Thal (eg, constipation, neuropathy, tremors) were not 
observed. Toxicities associated with lenalidomide were 
primarily hematologic and reversible. The most common 
grade 3 or higher adverse events during lenalidomide therapy 
were neutropenia and thrombocytopenia. Grade 4 neutro-
penia occurred in 2 of 34 (5.8%) patients treated at 15 mg 
twice daily vs 4 of 68 (5.9%) patients treated with 30 mg 
daily. Grade 4 thrombocytopenia occurred in 2 (5.8%) of 
34 patients on 15 mg twice daily vs 2 of 68 patients (2.9%) 
treated with 30 mg daily. Deep vein thrombosis (DVT) 
was reported in 1 patient on the 30 mg daily and 2 patients 
(5.8%) on the 15 mg twice-daily treated regimen. Sedation 
or neurologic toxicities were not observed in most of these 
studies (Richardson et al 2006). The differences in the side 
effect proﬁ  le between Thal and lenalidomide may reﬂ  ect 
distinct patterns of antiangiogenic, cytokine-related, micro-
environmental, and immunomodulatory activity, rather than 
distinct separate mechanisms of action.
In phase III trials of lenalidomide plus Dex for newly 
diagnosed MM patients, 47% of patients experienced grade 
III or higher nonhematologic toxicity. The most common 
adverse effects were fatigue (15%), muscle weakness (6%), 
anxiety (6%), pneumonitis (6%), and rash (6%) (Rajkumar 
et al 2006a). Recently, a randomized phase III trial of 
lenalidomide plus high-dose Dex versus lenalidomide plus 
low-dose Dex in newly diagnosed MM has also reported 
by Rajkumar et al (2006b). In this study, patients in both 
arms received lenalidomide 25 mg/day orally on days 1–21 
every 28 days. In addition, patients in the high-dose Dex 
arm received Dex 40 mg on days 1–4, 9–12, and 17–20 
orally every 28 days, while patients in the low-dose Dex Therapeutics and Clinical Risk Management 2008:4(1) 135
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arm received Dex 40 mg on days 1, 8, 15, and 22 orally 
every 28 days. Although response rate (RR) has not yet 
been reported, toxicity rates are higher in the high-dose 
Dex arm than low-dose Dex arm. For example, Grade 3 
and above toxicities in cardiac ischemia (2.7% vs 0.5%), 
hypercalcemia (5.8% vs 1.8%), infection (18.8% vs 9%), 
thromboembolism (18.4% vs 5.4%), and non-hematologic 
toxicities (22% vs 12.6%) are higher in high-dose Dex arm 
than low-dose Dex arm. If RR is similar in both arms, dos-
age of Dex can be reduced to 25 mg.
Conclusion
Lenalidomide plus Dex treatment is highly effective in 
both preclinical and clinical studies. It is one of the prom-
ising treatment options against both relapsed/refractory 
and newly diagnosed MM patients. Adverse effects of this 
combination can be markedly reduced by lowering the 
Dex dosage.
Future directions
Lenalidomide plus Dex treatment can be further combined 
with other novel or conventional agents to improve patient 
outcome in MM. Indeed, potent Akt inhibitor Perifosine, 
proteasome inhibitor bortezomib (Velcade®; Millennium 
Pharmaceuticals Inc.), and anti-angiogenic agent bevaci-
zumab (Avastin®; Genentech) are already under evaluation 
in combination clinical trials.
Acknowledgments
Supported by National Institutes of Health Grant PO-1 
78378 and RO-1 CA 50947; the Doris Duke Distinguished 
Clinical Research Scientist Award (KCA); the Multiple 
Myeloma Research Foundation (TH, NR, KCA); and the 
Myeloma Research Fund (KCA).
References
Akiyama M, Hideshima T, Hayashi T, et al. 2002. Cytokines modulate 
telomerase activity in a human multiple myeloma cell line. Cancer 
Res, 62:3876–82.
Anderson G, Gries M, Kurihara N, et al. 2006. Thalidomide derivative 
CC-4047 inhibits osteoclast formation by down-regulation of PU.1. 
Blood, 107:3098–105.
Attal M, Harousseau JL, Facon T, et al. 2003. Single versus double auto-
logous stem-cell transplantation for multiple myeloma. N Engl J Med, 
349:2495–502.
Bahlis NJ, Mansoor A, Lategan JC, et al. 2006. Lenalidomide overcomes 
poor prognosis conferred by deletion of chromosome 13 and t(4; 14) 
in multiple myeloma: MM016 Trial. Blood, 108:1016a.
Bartlett JB, Dredge K, Dalgleish AG. 2004. The evolution of thalidomide and 
its IMiD derivatives as anticancer agents. Nat Rev Cancer, 4:314–22.
Carrasco DR, Tonon G, Huang Y, et al. 2006. High-resolution genomic 
proﬁ  les deﬁ  ne distinct clinico-pathogenetic subgroups of multiple 
myeloma patients. Cancer Cell, 9:313–25.
Catley L, Tai YT, Shringarpure R, et al. 2004. Proteasomal degradation of 
topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, 
Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in 
SN38-mediated cytotoxicity against multiple myeloma. Cancer Res, 
64:8746–53.
Chauhan D, Catley L, Li G, et al. 2005. A novel orally active proteasome 
inhibitor induces apoptosis in multiple myeloma cells with mechanisms 
distinct from Bortezomib. Cancer Cell, 8:407–19.
Chauhan D, Hideshima T, Rosen S, et al. 2001. Apaf-1/cytochrome c 
independent and Smac dependent induction of apoptosis in multiple 
myeloma cells. J Biol Chem, 276:24453–6.
Chauhan D, Li G, Hideshima T, et al. 2004. Blockade of ubiquitin-
conjugating enzyme CDC34 enhances anti-myeloma activity of 
Bortezomib/Proteasome inhibitor PS-341. Oncogene, 23:3597–602.
Chauhan D, Uchiyama H, Akbarali Y, et al. 1996. Multiple myeloma cell 
adhesion-induced interleukin-6 expression in bone marrow stromal 
cells involves activation of NF-kB. Blood, 87:1104–12.
Corral LG, Haslett PAJ, Muller GW, et al. 1999. Differential cytokine modu-
lation and T cell activation by two distinct classes of thalidomide ana-
logues that are potent inhibitors of TNF-α. J Immunol, 163:380–6.
D’Amato RJ, Loughman MS, Flynn E, et al. 1994. Thalidomide is an inhi-
bitor of angiogenesis. Proc Natl Acad Sci USA, 91:4082–5.
Damiano JS, Cress AE, Hazlehurst LA, et al. 1999. Cell adhesion mediated 
drug resistance (CAM-DR): Role of integrins and resistance to apoptosis 
in human myeloma cell lines. Blood, 93:1658–67.
Dankbar B, Padro T, Leo R, et al. 2000. Vascular endothelial growth factor 
and interleukin-6 in paracrine tumor-stromal cell interactions in multiple 
myeloma. Blood, 95:2630–6.
Davies FE, Raje N, Hideshima T, et al. 2001. Thalidomide and immu-
nomodulatory derivatives augment natural killer cell cytotoxicity in 
multiple myeloma. Blood, 98:210–16.
Desikan R, Barlogie B, Sawyer J, et al. 2000. Results of high-dose therapy 
for 1000 patients with multiple myeloma: durable complete remissions 
and superior survival in the absence of chromosome 13 abnormalities. 
Blood, 95:4008–10.
Dredge K, Horsfall R, Robinson SP, et al. 2005. Orally administered 
lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endo-
thelial cell migration and Akt phosphorylation in vitro. Microvasc 
Res, 69:56–63.
Fermand J-P, Ravaud P, Chevret S, et al. 1998. High-dose therapy and 
autologous peripheral blood stem cell transplantation in multiple 
myeloma: Up-front or rescue treatment? Results of a multicenter 
sequential randomized clinical trial. Blood, 92:3131–6.
Fonseca R, Barlogie B, Bataille R, et al. 2004. Genetics and cytogenetics of 
multiple myeloma: a workshop report. Cancer Res, 64:1546–58.
Fujita J, Mestre JR, Zeldis JB, et al. 2001. Thalidomide and its analogues 
inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. 
Clin Cancer Res, 7:3349–55.
Fujita K, Asami Y, Tanaka K, et al. 2004. Anti-angiogenic effects of 
thalidomide: expression of apoptosis-inducible active-caspase-3 in a 
three-dimensional collagen gel culture of aorta. Histochem Cell Biol, 
122:27–33.
Gregory WM, Richards MA, Malpas JS. 1992. Combination chemo-
therapy versus melphalan and prednisolone in the treatment of 
multiple myeloma: an overview of published trials. J Clin Oncol, 
10:334–42.
Group MTsC. 1998. Combination chemotherapy versus melphalan plus 
prednisone as treatment for multiple myeloma: an overview of 6,633 
patients from 27 randomized trials. J Clin Oncol, 16:3832–42.
Haslett PA, Hanekom WA, Muller G, et al. 2003. Thalidomide and a 
thalidomide analogue drug costimulate virus-speciﬁ  c CD8+ T cells 
in vitro. J Infect Dis, 187:946–55.
Hayashi T, Hideshima T, Akiyama M, et al. 2005. Molecular mechanisms 
whereby immunomodulatory drugs activate natural killer cells: clinical 
application. Br J Haematol, 128:192–203.
Hideshima T, Anderson KC. 2002. Molecular mechanisms of novel thera-
peutic approaches for multiple myeloma. Nat Rev Cancer, 2:927–37.Therapeutics and Clinical Risk Management 2008:4(1) 136
Hideshima et al
Hideshima T, Bergsagel PL, Kuehl WM, et al. 2004. Advances in biology 
of multiple myeloma: clinical applications. Blood, 104:607–18.
Hideshima T, Catley L, Yasui H, et al. 2006. Perifosine, an oral bioac-
tive novel alkylphospholipid, inhibits Akt and induces in vitro 
and in vivo cytotoxicity in human multiple myeloma cells. Blood, 
107:4053–62.
Hideshima T, Chauhan D, Richardson P, et al. 2002. NF-κB as a therapeutic 
target in multiple myeloma. J Biol Chem, 277:16639–47.
Hideshima T, Chauhan D, Shima Y, et al. 2000. Thalidomide and its ana-
logues overcome drug resistance of human multiple myeloma cells to 
conventional therapy. Blood, 96:2943–50.
Hideshima T, Nakamura N, Chauhan D, et al. 2001. Biologic sequelae 
of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. 
Oncogene, 20:5991–6000.
Hideshima T, Richardson P, Anderson KC. 2003. Novel therapeutic 
approaches for multiple myeloma. Immunol Rev, 194:164–76.
Hideshima T, Richardson P, Chauhan D, et al. 2001. The proteasome inhi-
bitor PS-341 inhibits growth, induces apoptosis, and overcomes drug 
resistance in human multiple myeloma cells. Cancer Res, 61:3071–6.
Keifer JA, Guttridge DC, Ashburner BP, et al. 2001. Inhibition of NF-κB 
activity by thalidomide through suppression of IkappaB kinase activity. 
J Biol Chem, 276:22382–7.
Knop S, Gerecke C, Topp MS, et al. 2006. Lenalidomide (Revlimid), adria-
mycin and dexamethasone chemotherapy (RAD) is safe and effective 
in treatment of relapsed multiple myeloma -ﬁ  rst results of a German 
multicenter phase I/II trial. Blood, 108:125a.
Kuehl WM, Bergsagel PL. 2002. Multiple myeloma: evolving genetic events 
and host interactions. Nat Rev Cancer, 2:175–87.
LeBlanc R, Hideshima T, Catley LP, et al. 2004. Immunomodulatory drug 
costimulates T cells via the B7-CD28 pathway. Blood, 103:1787–90.
Lenhoff S, Hjorth M, Holmberg E, et al. 2000. Impact on survival of high-
dose therapy with autologous stem cell support in patients younger than 
60 years with newly diagnosed multiple myeloma: a population-based 
study. Blood, 95:7–11.
Lentzsch S, Rogers MS, LeBlanc R, et al. 2002. S-3-Amino-phthalimido-
glutarimide inhibits angiogenesis and growth of B-cell neoplasias in 
mice. Cancer Res, 62:2300–5.
Massaia M, Borrione P, Battaglio S, et al. 1999. Idiotype vaccination in 
human myeloma: generation of tumor-speciﬁ  c immune responses after 
high-dose chemotherapy. Blood, 94:673–83.
Mitsiades CS, Mitsiades N, Munshi NC, et al. 2004. Focus on multiple 
myeloma. Cancer Cell, 6:439–44.
Mitsiades N, Mitsiades CS, Poulaki V, et al. 2002. Apoptotic signaling 
induced by immunomodulatory thalidomide analogs in human multiple 
myeloma cells: therapeutic implications. Blood, 99:4525–30.
Muller GW, Chen R, Huang SY, et al. 1999. Amino-substituted thalidomide 
analogs: potent inhibitors of TNF-α production. Bioorg Med Chem 
Lett, 9:1625–30.
Raje N, Kumar S, Hideshima T, et al. 2004. Combination of the mTOR 
inhibitor Rapamycin and Revlimid (CC-5013) has synergistic activity 
in multiple myeloma. Blood, 104:4188–93.
Rajkumar SV, Jacobus S, Callander N, et al. 2006b. A randomized phase III 
trial of lenalidomide plus high-dose dexamethasone versus lenalidomide 
plus low-dose dexamethasone in newly diagnosed multiple myeloma 
(E4A03): a trial coordinated by the Eastern Cooperative Oncology 
Group. Blood, 108:239a.
Rajkumar SV, Blood E, Vesole D, et al. 2006a. Phase III clinical trial of 
thalidomide plus dexamethasone compared with dexamethasone alone 
in newly diagnosed multiple myeloma: a clinical trial coordinated by the 
Eastern Cooperative Oncology Group. J Clin Oncol, 24:431–6.
Rajkumar SV, Hayman SR, Lacy MQ, et al. 2005. Combination therapy 
with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed 
myeloma. Blood, 106:4050–3.
Richardson P, Jagannath S, Schlossman R, et al. 2002. A multi-center, 
randomized, phase II study to evaluate the efﬁ  cacy and safety of two 
CC-5013 dose regimens when used alone or in combination with dexa-
meyhasone (Dex) for the treatment of relapsed or refractory multiple 
myeloma (MM). Blood, 100:104a.
Richardson PG, Blood E, Mitsiades CS, et al. 2006. A randomized phase 
2 study of lenalidomide therapy for patients with relapsed or relapsed 
and refractory multiple myeloma. Blood, 108:3458–64.
Richardson PG, Schlossman RL, Weller E, et al. 2002. Immunomodula-
tory drug CC-5013 overcomes drug resistance and is well tolerated in 
patients with relapsed multiple myeloma. Blood, 100:3063–7.
Rowland TL, McHugh SM, Deighton J, et al. 2001. Differential effect of 
thalidomide and dexamethasone on the transcription factor NF-κB. 
Int Immunopharmacol, 1:49–61.
Shannon E, Aseffa A, Pankey G, et al. 2000. Thalidomide’s ability to augment the 
synthesis of IL-2 in vitro in HIV-infected patients is associated with the per-
centage of CD4+ cells in their blood. Immunopharmacology, 46:175–9.
Singhal S, Mehta J, Desikan R, et al. 1999. Antitumor activity of thalidomide 
in refractory multiple myeloma. N Engl J Med, 341:1565–71.
Stewart AK, Scanga SE, Zhu YX, et al. 2004. Inhibition of Wnt pathway 
signaling by thalidomide and revlimid: studies in a drosophila model 
system. Blood, 104:916a.
Tai YT, Li XF, Catley L, et al. 2005. Immunomodulatory drug lenalidomide 
(CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity 
in human multiple myeloma: clinical implications. Cancer Res, 
65:11712–20.
Terpos E, Dimopoulos MA, Sezer O. 2007. The effect of novel anti-
myeloma agents on bone metabolism of patients with multiple myeloma. 
Leukemia, 21:1875–84.
Tseng S, Pak G, Washenik K, et al. 1996. Rediscovering thalidomide: a 
review of its mechanism of action, side effects, and potential uses. 
J Am Acad Dermatol, 35:969–79.
Weber D, Wang M, Chen C, et al. 2006. Lenalidomide plus high-dose 
dexamethasone provides improved overall survival compared to high-
dose dexamethasone alone for relapsed or refractory multiple myeloma 
(MM): results of 2 phase III studies (MM-009, MM-010) and subgroup 
analysis of patients with impaired renal function. Blood, 108:1012a.
Wu A, Schefﬂ  er MR. 2004. Multi-dose phamacokinetics and safety of 
CC-5013 in 15 multiple myeloma patients. J Clin Oncol, 22:141s.